Tresiba Pediatric (Under 12): Caregiver Administration Guidance

What Is Tresiba and Why It Is Used in Young Children

Tresiba is the brand name for insulin degludec, a basal insulin analog produced by Novo Nordisk. Its approval for children aged 1 year and older was granted by the FDA based on pharmacokinetic and efficacy data showing a predictable, flat action profile lasting up to 42 hours. 1

Mechanism and Duration Compared With Other Basal Insulins

Insulin degludec forms soluble multi-hexamers at the injection site. Those multi-hexamers slowly dissociate, releasing monomers into circulation at a steady rate. The result is a half-life of approximately 25 hours and a total action time up to 42 hours, longer than insulin glargine U-100 (roughly 24 hours) or NPH insulin (12 to 18 hours). 2

That flat, peakless profile matters specifically for pediatric caregivers. A child's meal schedule and activity level change daily. With NPH or even glargine, an unexpected nap or skipped snack can coincide with the insulin's peak and cause significant hypoglycemia. Degludec's flat profile reduces, though does not eliminate, that risk. 3

Approved Indications in the Under-12 Population

The FDA label approves Tresiba for children aged 1 year and older with either type 1 or type 2 diabetes requiring basal insulin. The U-200 formulation is approved only for adults. Caregivers must use the U-100 FlexTouch pen for any child under 18. 1

Dose Selection and Starting Insulin Degludec in Children Under 12

Prescribers, not caregivers, set the starting dose. Caregivers must understand the dose rationale to catch errors, so a working knowledge of how numbers are chosen is part of safe administration.

Insulin-Naive Children

For children with type 1 diabetes who have never used insulin, the standard approach allocates approximately 40 to 50% of the calculated total daily dose (TDD) to basal insulin. TDD is typically estimated at 0.5 units/kg/day at diagnosis, rising to 0.7 to 1.0 units/kg/day during established disease. The ADA's 2024 Standards of Care in Diabetes state that "basal insulin should be initiated at 10 units/day or 0.1 to 0.2 units/kg/day, with titration based on fasting glucose values." 4 Those figures apply to adults and adolescents; for children under 12, starting doses are often lower and individualized.

Transitioning From Another Basal Insulin

A unit-to-unit conversion is used when switching from insulin glargine U-100 or insulin detemir to insulin degludec. Because degludec is slightly more potent per unit than detemir in some patients, some clinicians reduce the starting degludec dose by 20% when transitioning from detemir, then titrate upward. The FDA prescribing information recommends starting at the same unit dose when switching from glargine. 1

Dose Titration Guidance

Titration typically occurs in increments of 1 to 2 units every 3 to 4 days, guided by fasting blood glucose readings. A fasting glucose target of 80 to 130 mg/dL is widely applied in pediatric type 1 diabetes management, per ADA pediatric glycemia recommendations. 4 Caregivers should never adjust the dose without explicit instruction from the prescribing clinician.

Step-by-Step FlexTouch Pen Administration Technique

Correct injection technique reduces pain, lipohypertrophy, and erratic insulin absorption. The following steps apply to the Tresiba U-100 FlexTouch pen. 5

Preparing the Pen

1. Wash hands with soap and water for at least 20 seconds.
2. Inspect the cartridge window. Insulin degludec should appear clear and colorless. Discard if cloudy, colored, or containing particles. 1
3. Attach a new pen needle. Remove the outer cap, peel the protective tab from the needle, screw the needle straight onto the pen, and remove both needle caps.
4. Perform a flow check (prime) with 2 units: turn the dose selector to 2, hold the pen with the needle pointing up, tap to bring air bubbles up, and press the dose button until "0" is in the window. A drop of insulin should appear at the needle tip. Repeat if no drop appears. 1

Selecting and Confirming the Dose

Turn the dose selector until the prescribed dose is visible in the dose counter window. The FlexTouch pen dials in 1-unit increments, clicking audibly. Confirm the correct number before touching the injection site. This confirmation step is where caregiver errors most often occur.

Choosing the Injection Site

Approved injection sites are the abdomen, upper outer thigh, and upper outer arm. In children under 12, the abdomen and thigh are the most practical sites. Rotate sites systematically within the same anatomical region at each injection. Repeating the same spot leads to lipohypertrophy, which slows and unpredictably delays insulin absorption. 6

A 2016 study of 388 insulin-using patients found that 49% had palpable lipohypertrophy, and those with lipohypertrophy had a mean HbA1c 0.7% higher and required on average 5 more units per day than those without it. 6 Systematic rotation matters.

Injecting and Post-Injection Steps

1. Clean the site with an alcohol swab. Let it dry for 10 seconds to prevent stinging.
2. Pinch the skin gently (2 fingers) if the child has minimal subcutaneous fat. For a child with adequate fat tissue and a 4 mm needle, a pinch is usually unnecessary.
3. Insert the needle at a 90-degree angle. Press the dose button fully and hold for a slow count of six before withdrawing. Counting to six allows the full dose to deliver and prevents dropback. 7
4. Remove the needle without rubbing the site.
5. Replace the outer needle cap, unscrew the needle, and dispose in a sharps container. Never recap with the inner cap. 8

Storage Requirements for Tresiba in Pediatric Households

Unopened Pens

Unopened Tresiba U-100 FlexTouch pens must be stored in a refrigerator at 36 to 46°F (2 to 8°C). Keep pens away from the cooling element to avoid freezing. Frozen insulin degludec must be discarded; freezing disrupts the multi-hexamer structure and alters pharmacokinetics. 1

In-Use Pens

Once opened (first use), the pen may be stored at room temperature below 86°F (30°C) for up to 56 days. Mark the date of first use on the pen cap with a permanent marker. The 56-day in-use limit applies regardless of how much insulin remains. 1

Cold insulin injection is more painful. Removing the pen from the refrigerator 30 to 60 minutes before the scheduled injection makes the process more tolerable for young children. Never warm the pen by microwaving or placing in hot water.

Travel and School Considerations

Insulin degludec should not be stored in checked baggage during air travel (risk of freezing in cargo). Carry-on storage with a cool pack keeps the pen below 86°F. When a child's dose is administered at school, the in-use pen can remain at room temperature in the school nurse's office. ADA guidance advises that school diabetes management plans include a written protocol for insulin storage and administration. 9

Timing of Daily Injections

Insulin degludec's 42-hour duration means it builds a stable steady-state concentration in the blood after 2 to 3 days of once-daily dosing. 2 This property gives caregivers practical flexibility.

Consistency Is the Priority

Administer Tresiba at the same time each day. The FDA label allows a minimum interval of 8 hours between doses if a scheduled dose is missed and needs to be given late. 1 Evening dosing (before dinner or at bedtime) is common in pediatric practice because it aligns basal coverage with overnight fasting, but morning dosing also works if the child's schedule supports it.

Missed-Dose Protocol

If a dose is missed and the next scheduled dose is more than 8 hours away, give the missed dose as soon as remembered. If fewer than 8 hours remain before the next scheduled dose, skip the missed dose entirely and resume the regular schedule the following day. Never double dose. 1

Recognizing and Managing Hypoglycemia in Children Under 12

Hypoglycemia is the most common acute complication of basal insulin therapy in children. The Endocrine Society defines hypoglycemia as a blood glucose <70 mg/dL with or without symptoms, and a clinically significant episode as <54 mg/dL. 10

Symptoms by Age

Children under 5 often cannot verbalize hypoglycemia symptoms. Caregivers should watch for pallor, trembling, irritability, difficulty waking, or sweating. Children aged 6 to 11 may report shakiness, hunger, dizziness, or headache. Behavioral changes such as sudden crying or uncharacteristic clumsiness are also signals. 11

The "Rule of 15" for Mild-to-Moderate Hypoglycemia

If the child is conscious and able to swallow, give 15 grams of fast-acting carbohydrate (4 oz of juice, 3 to 4 glucose tablets, or 1 tube of glucose gel). Recheck blood glucose in 15 minutes. If still <70 mg/dL, repeat. Once blood glucose returns to >80 mg/dL and the child feels better, offer a small snack if the next meal is more than an hour away. 4

Severe Hypoglycemia: Glucagon

Severe hypoglycemia (unconsciousness or seizure) requires glucagon. Prescribers often co-prescribe nasal glucagon (Baqsimi, 3 mg) or injectable glucagon kit for children on basal insulin. A 2021 systematic review in The Lancet Diabetes and Endocrinology confirmed nasal glucagon was as effective as injectable glucagon for treating severe hypoglycemia in pediatric trials, with successful treatment in 97.3% of episodes. 12 After glucagon administration, call emergency services.

Monitoring Blood Glucose and Adjusting Expectations

Target Ranges for Children Under 12

The ADA's 2024 pediatric glycemia targets recommend a pre-meal glucose of 80 to 130 mg/dL and a time-in-range (TIR, 70 to 180 mg/dL) of greater than 70% for most children with type 1 diabetes. 4 Overnight TIR >80% is an emerging secondary target. Caregivers using continuous glucose monitoring (CGM) should review overnight traces at least weekly to identify patterns of nocturnal hypoglycemia or hyperglycemia that warrant a dose adjustment call to the diabetes team.

When to Contact the Prescriber

Contact the prescribing clinician if:

• Fasting glucose is consistently above 180 mg/dL for three consecutive mornings.
• More than two blood glucose values below 70 mg/dL occur in one week without an obvious cause (missed meal, extra activity).
• The child has one episode of severe hypoglycemia.
• Weight changes more than 5% over four weeks (weight gain alters insulin requirements). 13

The table below summarizes a practical caregiver monitoring framework developed from FDA label parameters, ADA 2024 Standards, and Endocrine Society guidelines:

| Situation | Action | Timing | |---|---|---| | Fasting glucose 80 to 130 mg/dL consistently | Continue current dose | Ongoing | | Fasting glucose >180 mg/dL x 3 mornings | Call prescriber for titration | Within 24 hours | | Blood glucose <70 mg/dL with symptoms | Rule of 15; recheck in 15 min | Immediate | | Blood glucose <54 mg/dL or unconscious | Glucagon; call 911 | Immediate | | Injection site feels lumpy or hard | Report to clinician; rotate sites | At next appointment or sooner | | Pen stored >86°F for over 2 hours | Discard pen; use new one | Immediately |

Clinical Evidence Supporting Degludec Use in Children Under 12

BEGIN Young 1 Trial

The BEGIN Young 1 trial (N=167 children aged 1 to 17 years with type 1 diabetes) compared insulin degludec once daily with insulin detemir once or twice daily over 26 weeks. Degludec achieved a statistically non-inferior reduction in HbA1c (mean change: -0.1% vs. -0.3% for detemir), with a confirmed hypoglycemia rate of 20.7 episodes per patient-year compared with 28.5 for detemir (rate ratio 0.73, P<0.05). 14 That is approximately a 27% lower confirmed hypoglycemia rate with degludec.

Nocturnal Hypoglycemia Reduction

Nocturnal hypoglycemia is a particular concern for caregivers of young children who cannot alert adults when symptoms occur. In BEGIN Young 1, nocturnal confirmed hypoglycemia occurred at a rate of 2.9 episodes per patient-year with degludec versus 4.4 with detemir (rate ratio 0.66). 14 Fewer overnight lows translates directly into less nighttime caregiver monitoring burden, though overnight CGM checks remain standard of care.

Pharmacokinetic Data in Young Children

A dedicated PK/PD study in children aged 1 to 5 years with type 1 diabetes (N=24) found that insulin degludec's glucose-lowering effect was evenly distributed over 24 hours, consistent with adult data, with a coefficient of variation for the area under the glucose-infusion-rate curve of approximately 20%, lower than for NPH insulin. 15 Low day-to-day variability in pharmacokinetics is a meaningful safety attribute for caregivers managing young children.

Injection Site Considerations Specific to Young Children

Children under 12 have less subcutaneous fat than adults and adolescents. That anatomical fact changes needle selection and injection angle decisions significantly.

Needle Length

A 4 mm pen needle is recommended for children regardless of body weight by the Forum for Injection Technique and Therapy Expert Recommendations (FITTER) guidelines, provided the skin is pinched appropriately for very lean children. An 8 mm needle carries a 50% risk of intramuscular injection in children, which accelerates insulin absorption unpredictably and increases pain. 7

Lipohypertrophy Prevention

Children are more adherent to a rotation scheme when caregivers use a written or visual rotation map. A simple diagram with numbered injection spots, rotated in sequence at each dose, reduces lipohypertrophy risk. The diabetes team should palpate injection sites at every clinic visit, because children often do not report site abnormalities. 6

Communicating With the Pediatric Diabetes Team

Effective caregiver-clinician communication is a core component of safe insulin management. The ADA and American Academy of Pediatrics both recommend formal diabetes management plans for school-age children, including written protocols for insulin administration, hypoglycemia treatment, and emergency contacts. 9

Caregivers should bring the in-use FlexTouch pen to every clinic visit so the diabetes educator can inspect injection technique and site condition. Dose adjustments should be documented in writing or via a secure patient portal message to prevent transcription errors. The treating endocrinologist or diabetes nurse educator should be the first point of contact for any dosing question, not a pharmacy or general information line.

Keep a log of:

• Time of each injection
• Dose given (units)
• Blood glucose before injection
• Any hypoglycemia episodes and how they were treated
• Injection site used (to track rotation)

A one-month blood glucose and injection log reviewed at clinic visits allows the prescriber to identify patterns and titrate safely. 16

Device Safety: Pen Needles, Disposal, and Avoiding Medication Errors

Single-Use Needles Only

Pen needles must be used once. Reuse dulls the needle tip, increases injection pain, raises infection risk, and leads to inaccurate dosing because residual insulin in the needle can block the next dose. A 2016 survey of 1,400 insulin pen users found that 43% reused needles, with needle reuse correlated with higher HbA1c and more frequent injection site complications. 17

Sharps Disposal

Used needles must go directly into an FDA-cleared sharps container. Household disposal in regular trash or recycling creates needle-stick injury risk for sanitation workers and children. The FDA provides a state-by-state guide to sharps disposal programs. 8

Preventing Mix-Ups With Mealtime Insulin

Many children on basal insulin also use a rapid-acting insulin (such as insulin aspart or lispro) for meals. Tresiba (clear) and most rapid-acting analogs (also clear) look identical in the pen. Caregivers must confirm the pen label before every injection. Color-coded pen caps or pen labels can reduce mix-up risk. The FDA has received reports of wrong-insulin errors in pediatric patients; clear labeling and storage separation are the primary defenses. 18